The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

Reston, VA—Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177 Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

In terms of patient selection, workgroup members agreed that PSMA PET should be performed within three months of treatment or since progression on the last therapy to ensure that the current disease ...

Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect ...

@2024 - All Right Reserved.

The researchers also assessed a prognostic biomarker, fluorodeoxyglucose (FDG) PET. A high volume of disease on FDG-PET (metabolic tumor volume [MTV] > 200 mL) was associated with a worse prognosis ...